Human Recombinant ALB - His Tagged
Reference ID:KB-3904
Western Blot
Flow Cytometry
Gene of Interest
Gene Synonyms:ALB;GIG20;GIG42;PRO0903;PRO1708;PRO2044;PRO2619;PRO2675;UNQ696/PRO1341
Protein Names:Serum albumin
Accession Data
Organism:Homo sapiens (Human)
Mass (kDa):693.67
Length (aa):609
Proteomics (Proteome ID):UP000005640
Proteomics (Chromosome): Chromosome 4
Polymorphism: A variant structure of albumin could lead to increased binding of zinc resulting in an asymptomatic augmentation of zinc concentration in the blood. The sequence shown is that of variant albumin A.
Binding Site:BINDING 264 264 Bilirubin.
Function [CC]:Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc. {ECO:0000269|PubMed:19021548}.
Metal Binding:METAL 27 27 Copper. {ECO:0000250}.; METAL 91 91 Zinc.; METAL 123 123 Zinc.; METAL 271 271 Zinc.; METAL 273 273 Zinc.
Site:SITE 28 28 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 44 44 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 65 65 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 88 88 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 97 97 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 117 117 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 130 130 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 160 160 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 183 183 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 198 198 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 205 205 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 214 214 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 219 219 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 223 223 Aspirin-acetylated lysine.; SITE 229 229 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 236 236 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 264 264 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 286 286 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 298 298 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 310 310 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 383 383 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 396 396 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 413 413 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 426 426 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 438 438 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 456 456 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 460 460 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 490 490 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 499 499 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 524 524 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 543 543 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 548 548 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 562 562 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 565 565 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 581 581 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 584 584 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 588 588 Not glycated. {ECO:0000269|PubMed:15047055}.; SITE 598 598 Not glycated. {ECO:0000269|PubMed:15047055}.
Tissue Specificity:Plasma.
Disease:Hyperthyroxinemia, familial dysalbuminemic (FDAH) [MIM:615999]: A disorder characterized by abnormally elevated levels of total serum thyroxine (T4) in euthyroid patients. It is due to abnormal serum albumin that binds T4 with enhanced affinity. {ECO:0000269|PubMed:7852505, ECO:0000269|PubMed:8048949, ECO:0000269|PubMed:9329347, ECO:0000269|PubMed:9589637}. Note=The disease is caused by mutations affecting the gene represented in this entry.; Analbuminemia (ANALBA) [MIM:616000]: A rare autosomal recessive disorder manifested by the presence of a very low amount of circulating serum albumin. Affected individuals manifest mild edema, hypotension, fatigue, and, occasionally, lower body lipodystrophy (mainly in adult females). The most common biochemical finding is hyperlipidemia, with a significant increase in the total and LDL cholesterol concentrations, but normal concentrations of HDL cholesterol and triglycerides. {ECO:0000269|PubMed:8134387}. Note=The disease is caused by mutations affecting the gene represented in this entry.
Reagent Data
Region:Asp 25 - Leu 609
Molecular Weight:67.3
Purification System:Chromatography
Formulation:Sterile-filtered colorless solution
Formulation Concentration:1 mg/ml
Buffer Volume:Standard
Buffer Solution:PBS
Endotoxin Level:< 1%
Aggregate Tested By:SDS-PAGE
Endotoxin Screened:< 0.1 ng/ug
Purity:> 98%
Determined: SDS-PAGE
Validated: RP-HPLC
Sample Handling
Stability:This bioreagent is stable at 4°C (short-term) and -70°C(long-term). After reconstitution, sample may be stored at 4°C for 2-7 days and below -18°C for future use.
Preparation:Reconstitute in sterile distilled H2O to no less than 100 ug/ml; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.